www.hivandhepatitis.com

1. Treat Everyone Living with HIV

In September the World Health Organization released updated guidelines calling for antiretroviral therapy (ART) for everyone diagnosed with HIV regardless of CD4 T-cell count, as well as pre-exposure prophylaxis for people at substantial risk of infection. WHO estimates that the recommendations, if widely adopted, could avert 21 million deaths and prevent 28 million new infections worldwide by 2030.

Read more:

8. Long-term HIV Remission and Post-Treatment Control

A young woman who was infected with HIV at birth and received very early antiretroviral therapy (ART) as a baby has maintained a viral load below the limit of detectability of standard tests for more than 12 years after stopping treatment, shedding more light on "post-treatment control" as a potential functional cure strategy.

Read more:

6. New TAF Version of Tenofovir Approved in Combo Pill

In November the U.S. Food and Drug Administration announced the approval of Gilead Sciences' Genvoya, a new single-tablet regimen containing the integrase inhibitor elvitegravir, the booster cobicistat, emtricitabine, and tenofovir alafenamide or TAF -- a new formulation that is easier on the kidneys and bones than the older tenofovir disoproxil fumarate (TDF).

Read more:

San Francisco AIDS Foundation Opens Strut Health and Wellness Center2

TEXT

Read more:

7. Simplified Dolutegravir Therapy Looks Promising

The potent HIV integrase inhibitor dolutegravir (Tivicay) taken with a single well-tolerated NRTI fully suppressed viral load in people starting antiretroviral therapy for the first time, while dolutegravir monotherapy was able to keep HIV suppressed in most treatment-experienced people who started with undetectable viral load, according to studies presented at the European AIDS Conference in October.

Read more:

Happy New Year from HIVandHepatitis.com